[HTML][HTML] Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)
Context Prostate-specific membrane antigen (PSMA) targeting positron emission
tomography (PET) is emerging to become a reference imaging tool for the staging and …
tomography (PET) is emerging to become a reference imaging tool for the staging and …
Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for …
KM Chow, WZ So, HJ Lee, A Lee, DWT Yap… - European urology, 2023 - Elsevier
Context Whether prostate-specific membrane antigen positron emission tomography (PSMA-
PET) should replace conventional imaging modalities (CIM) for initial staging of intermediate …
PET) should replace conventional imaging modalities (CIM) for initial staging of intermediate …
The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance …
Background Multiparametric magnetic resonance imaging (MRI) is validated for the
detection of clinically significant prostate cancer (csPCa), although patients with …
detection of clinically significant prostate cancer (csPCa), although patients with …
[HTML][HTML] Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of …
Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer
Prostate-specific membrane antigen (PSMA) is highly expressed on most prostate cancer
(PCa) cells, and several PSMA ligands for PET imaging are now available worldwide. 68Ga …
(PCa) cells, and several PSMA ligands for PET imaging are now available worldwide. 68Ga …
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
WP Fendler, M Eiber, M Beheshti, J Bomanji… - European journal of …, 2023 - Springer
Here we aim to provide updated guidance and standards for the indication, acquisition, and
interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics …
interpretation of PSMA PET/CT for prostate cancer imaging. Procedures and characteristics …
Appropriate use criteria for prostate-specific membrane antigen PET imaging
Prostate cancer is the most common cancer diagnosis in men in the United States and a
leading cause of cancer-related morbidity and mortality (1). It can exist along a wide …
leading cause of cancer-related morbidity and mortality (1). It can exist along a wide …
[68Ga] Ga-PSMA versus [18F] PSMA positron emission tomography/computed tomography in the staging of primary and recurrent prostate cancer. A systematic review …
L Evangelista, T Maurer, H van der Poel… - European Urology …, 2022 - Elsevier
Context In the past 10 yr, several agents based on prostate-specific membrane antigen
(PSMA) for positron emission tomography imaging have been introduced in clinical practice …
(PSMA) for positron emission tomography imaging have been introduced in clinical practice …
The PRIMARY score: using intraprostatic 68Ga-PSMA PET/CT patterns to optimize prostate cancer diagnosis
Multiparametric MRI (mpMRI) is validated for the diagnosis of clinically significant prostate
cancer (csPCa). 68Ga-PSMA-11 PET/CT (68Ga-PSMA PET/CT) combined with mpMRI has …
cancer (csPCa). 68Ga-PSMA-11 PET/CT (68Ga-PSMA PET/CT) combined with mpMRI has …
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 …
Abstract Purpose To compare the Response Evaluation Criteria in Solid Tumors (RECIST)
1.1, the adapted Prostate Cancer Working Group Criteria 3 (aPCWG3), the adapted Positron …
1.1, the adapted Prostate Cancer Working Group Criteria 3 (aPCWG3), the adapted Positron …